[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-194745-105":53,"doc-detail-194745-en":126},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":119,"head_meta":121,"extra_data":123,"updated_unix":125},105,"en","serology-template-candidate-device-performance-results","Serology Template - Candidate Device Performance Results","","Serology template providing structured tables for antibody testing across multiple pathogens, including influenza A/B, HCV, HBV, Haemophilus influenzae, and selected coronaviruses, with results tracked for both IgM and IgG. Includes sections to record virus/bacteria/parasite antibody positivity by source sample type and results concordance, as well as evaluation matrices comparing outcomes with and without DTT treatment. Performance summaries are organized by days from symptom onset, sample counts, PPA/NPA rates, confidence intervals (95% CI), and agreement.",{"@graph":63,"@context":118},[64,80,101],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":36,"@type":70,"position":76},"https://docshare.wps.com/template/forms/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/serology-template-candidate-device-performance-results/194745/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/serology-template-candidate-device-performance-results/194745.png","ImageObject",442,249,{"name":88,"@type":89},"Evangeline","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-09-12","2026-09-03",true,{"@type":98,"interactionType":99,"userInteractionCount":73},"InteractionCounter",{"@type":100},"ViewAction",{"@type":102,"mainEntity":103},"FAQPage",[104,110,114],{"name":105,"@type":106,"acceptedAnswer":107},"Which antibody targets are listed for testing in this template?","Question",{"text":108,"@type":109},"The template lists antibody tests for influenza A and B (IgG and IgM), HCV, HBV, Haemophilus influenzae, multiple coronaviruses (229E, NL63, OC43, HKU1), ANA, respiratory syncytial virus (IgG and IgM), and HIV, among others shown.","Answer",{"name":111,"@type":106,"acceptedAnswer":112},"How are results compared between standard and DTT treatment in the template?",{"text":113,"@type":109},"It provides a replicates table that records results under “NO DTT Treatment (IgM/IgG)” and “DTT Treatment (IgM/IgG)”, plus expected results with DTT treatment and a result agreement column.",{"name":115,"@type":106,"acceptedAnswer":116},"How does the template evaluate candidate device performance?",{"text":117,"@type":109},"It summarizes candidate device results by days from symptom onset (e.g., 0-7, 8-14, and ≥15 days), reporting numbers of samples tested, counts of positive results for IgG and IgM, PPA values, and 95% confidence intervals.","https://schema.org",{"og:url":78,"og:type":120,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":122,"canonical":78},"index,follow",{"doc_id":124,"site_id":56},194745,1788442217,{"code":4,"msg":5,"data":127},{"doc_id":124,"user_id":128,"nickname":88,"user_avatar":129,"doc_module":9,"category_id":35,"category_name":36,"doc_title":59,"doc_description":61,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":4,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":15,"language":135,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":136,"faqs":137,"seo_title":138,"seo_description":61,"update_tm":125,"read_time":79},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","| anti-influenza A (IgG and IgM) |\n| --- |\n| anti-influenza B (IgG and IgM) |\n| anti-HCV (IgG and IgM) |\n| anti-HBV (IgG and IgM) |\n| anti-Haemophilus influenzae (IgG and IgM) |\n| anti-229E (alpha coronavirus) |\n| anti-NL63 (alpha coronavirus) |\n| anti-OC43 (beta coronavirus) |\n| anti-HKU1 (beta coronavirus) |\n| ANA |\n| anti-respiratory syncytial virus (IgG and IgM) |\n| anti-HIV |\n\n| Virus/Bacteria/Parasite Antibody positive | Source/ Sample type | Results* |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n\n| Sample ID | Replicates | Result\u003Cbr>NO DTT\u003Cbr>Treatment\u003Cbr>(IgM/IgG) | Result DTT Treatment\u003Cbr>(IgM/IgG) | Expected result with DTT treatment (IgM/IgG) | Result Agreement |\n| --- | --- | --- | --- | --- | --- |\n| 1 | 1 | +/+ | -/+ | -/+ | yes |\n|  | 2 | +/+ | -/+ | -/+ | yes |\n| 2 | 1 | +/+ | -/+ | -/+ | yes |\n|  | 2 | +/+ | -/+ | -/+ | yes |\n| 3 | 1 | +/+ | -/+ | -/+ | yes |\n|  | 2 | +/+ | -/+ | -/+ | yes |\n| 4 | 1 | +/+ | -/+ | -/+ | yes |\n|  | 2 | +/+ | -/+ | -/+ | yes |\n| 5 | 1 | +/+ | -/+ | -/+ | yes |\n|  | 2 | +/+ | -/+ | -/+ | yes |\n\n|  |  | \u003Cbr>Candidate Device Results |  |  |\n| --- | --- | --- | --- | --- |\n| Days from | Number of | Total Antibody | Total Antibody PPA | 95% CI |\n| \u003Cbr>Symptom | \u003Cbr>Samples | \u003Cbr>Positive results |  |  |\n| \u003Cbr>Onset | \u003Cbr>Tested |  |  |  |\n| 0-7 days | A | a | a/A (%) |  |\n| 8-14 days | B | b | b/B (%) |  |\n| ≥15 days | C | c | c/C (%) |  |\n\n\n|  | \u003Cbr>Candidate Device Results |  |\n| --- | --- | --- |\n| Number of Samples Tested | \u003Cbr>Negative Results | Overall NPA (95% CI) |\n| D | d | d/D (%) |\n\n\n|  |  | \u003Cbr>Candidate Device Results |  |  |\n| --- | --- | --- | --- | --- |\n| Days from | Number of | IgG Positive | \u003Cbr>IgG PPA | 95% CI |\n| \u003Cbr>Symptom | \u003Cbr>Samples | \u003Cbr>results |  |  |\n| \u003Cbr>Onset | \u003Cbr>Tested |  |  |  |\n| 0-7 days | A | a | a/A (%) |  |\n| 8-14 days | B | b | b/B (%) |  |\n| ≥15 days | C | c | c/C (%) |  |\n\n|  |  | \u003Cbr>Candidate Device Results |  |  |\n| --- | --- | --- | --- | --- |\n| Days from | Number of | IgM Positive | \u003Cbr>IgM PPA | 95% CI |\n| Symptom | Samples | \u003Cbr>results |  |  |\n| \u003Cbr>Onset | \u003Cbr>Tested |  |  |  |\n| 0-7 days | A | a | a/A (%) |  |\n| 8-14 days | B | b | b/B (%) |  |\n\n\n|  | C | c |  |  |\n| --- | --- | --- | --- | --- |\n\n\n|  |  | \u003Cbr>Candidate Device Results |  |  |\n| --- | --- | --- | --- | --- |\n| Days from Symptom Onset | Number of Samples Tested | IgG/IgM Combined Antibody Positive results | IgG/IgM Combined Antibody PPA | 95% CI |\n| 0-7 days | A | a | a/A (%) |  |\n| 8-14 days | B | b | b/B (%) |  |\n| ≥15 days | C | c | c/C (%) |  |\n\n\n|  | \u003Cbr>Candidate Device Results |  |\n| --- | --- | --- |\n| Number of Samples Tested | IgM/IgG Negative Results | NPA (95% CI) |\n| D | d | d/D (%) |\n\n|  |  | \u003Cbr>Candidate Device Results |  |  |\n| --- | --- | --- | --- | --- |\n| Days from | Number of | IgG Positive | \u003Cbr>IgG PPA | 95% CI |\n| Symptom | Samples | \u003Cbr>results |  |  |\n| \u003Cbr>Onset | \u003Cbr>Tested |  |  |  |\n| 0-7 days | A | a | a/A (%) |  |\n| 8-14 days | B | b | b/B (%) |  |\n\n\n|  | C | c |  |  |\n| --- | --- | --- | --- | --- |\n\n\n|  | \u003Cbr>Candidate Device Results |  |\n| --- | --- | --- |\n| Number of Samples Tested | \u003Cbr>IgG Negative Results | \u003Cbr>IgG NPA (95% CI) |\n| D | d | d/D (%) |\n\n\n|  |  | \u003Cbr>Candidate Device Results |  |  |\n| --- | --- | --- | --- | --- |\n| Days from | Number of | IgM Positive | \u003Cbr>IgM PPA | 95% CI |\n| \u003Cbr>Symptom | \u003Cbr>Samples | \u003Cbr>results |  |  |\n| \u003Cbr>Onset* | \u003Cbr>Tested |  |  |  |\n| 0-7 days | A | a | a/A (%) |  |\n| 8-14 days | B | b | b/B (%) |  |\n| 15-30 days | C | c | c/C (%) |  |","cbCaiiAoUKjcS61Y","https://ap.wps.com/l/cbCaiiAoUKjcS61Y","pdf",300442,"English","# Antibody Targets\n# Positive Result Summary\n# Replicates and DTT Comparison\n# Candidate Device Performance by Days Since Symptom Onset\n## IgG/IgM Performance Tables\n## Combined Antibody Performance\n## NPA (Negative) Performance","[{\"question\":\"Which antibody targets are listed for testing in this template?\",\"answer\":\"The template lists antibody tests for influenza A and B (IgG and IgM), HCV, HBV, Haemophilus influenzae, multiple coronaviruses (229E, NL63, OC43, HKU1), ANA, respiratory syncytial virus (IgG and IgM), and HIV, among others shown.\"},{\"question\":\"How are results compared between standard and DTT treatment in the template?\",\"answer\":\"It provides a replicates table that records results under “NO DTT Treatment (IgM/IgG)” and “DTT Treatment (IgM/IgG)”, plus expected results with DTT treatment and a result agreement column.\"},{\"question\":\"How does the template evaluate candidate device performance?\",\"answer\":\"It summarizes candidate device results by days from symptom onset (e.g., 0-7, 8-14, and ≥15 days), reporting numbers of samples tested, counts of positive results for IgG and IgM, PPA values, and 95% confidence intervals.\"}]","Serology Template - Candidate Device Performance Results | PDF"]